As of the January 13, 2025 data cutoff, patients with Cyclin E1+ PROC tumors who were response-evaluable (patients who had at least one scan after receiving azenosertib) demonstrated an ORR of 34. ...
Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to ...
As of the January 13, 2025 data cutoff, patients with Cyclin E1+ PROC tumors who were response-evaluable (patients who had at least one scan after receiving azenosertib) demonstrated an ORR of 34.9% ...
As of the January 13, 2025 data cutoff, patients with Cyclin E1+ PROC tumors who were response-evaluable (patients who had at least one scan after receiving azenosertib) demonstrated an ORR of 34. ...
But at the UIM E1 World Championship, these ingredients come together with spectacular results. Dubbed the 'Formula One of the Sea', this fast-growing sport has already attracted the backing of ...
Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ...
Notably, in PROC patients with a specific biomarker (Cyclin E1+), azenosertib achieved response rates of over 30%, with patients seeing improvements in disease control. While the company is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback